Check out the highlight video of Oramed’s recent webinar sharing data from its positive phase 2 clinical trial of oral insulin for #NASH with a Key Opinion Leader Discussion on the current treatment landscape.
You can see the entire webinar here: https://www.youtube.com/watch?v=YRYwZlojhwg
$ORMP #NASH #oralinsulin #diabetes #biotech
“Almost all my patients would prefer taking a once a day oral than taking any kind of injected therapy. I think this has broad applicability across multiple populations,” said Dr. Anne L. Peters, Keck School of Medicine of USC, in a recent webinar on “The Need for Oral Insulin in Type 2 Diabetes”.
To view the full webinar, click here: https://www.youtube.com/watch?v=yrWtf8PSgk0&t=10s
$ORMP #diabetes #type2diabetes #biotech #oralinsulin
“One in ten Americans has diabetes,” said President Joe Biden during his State of the Union address yesterday. As President #Biden urged in his speech, more must be done for the millions of Americans living with diabetes. Oramed Pharmaceuticals is working to revolutionize diabetes care with the development of an oral insulin capsule. Currently in Phase 3 trials under the #FDA, Oramed’s oral insulin has the potential to be the first oral insulin to reach market and transform diabetes care.
$ORMP #diabetes #SOTU #biotech
Last month we reached an important milestone as we signed a pre-purchase agreement with Vietnam's Tan Thanh Holdings for 10 million doses of Oravax Medical's oral Covid-19 vaccine in development.
"This agreement represents another step forward in the implementation of our long-term strategy. We view Tan Thanh Holdings as an ideal partner to bring our oral vaccine to Vietnam and the ASEAN region," stated Oramed Chief Executive Officer and Oravax Chairman Nadav Kidron.
$ORMP #biotech #COVID19
This week we reached an important milestone with the pre-purchase by Tan Thanh Holdings of Vietnam of 10 million doses of Oravax Medical's oral Covid-19 vaccine in development.
We look forward to sharing many more milestones in 2022!
Jim Cramer Mad Money on $ORMP: "That’s a good company, and I really like what they’re up to and I think you should go for it."
#biotech #oralinsulin
Nadav Kidron on i24NEWS
Watch: Oramed's CEO Nadav Kidron on i24news discusses oral insulin, Phase 3 trials and the potential to transform diabetes care
Nadav Kidron - Oral Insulin
Oramed's CEO Nadav Kidron explains that oral insulin can not only solve the problem of fear of needles, but also sends the insulin to the liver first. This means it mimics the physiological way the body works.
CEO Nadav Kidron Discusses Oramed's Oral Insulin Platform Technology
Oramed’s Protein Oral Delivery (POD) technology is a platform that allows injections to be delivered orally. This technology could not only revolutionize diabetes care but the future of injectable medications at large. Learn more.
The Best Treatment For Excess Glucose - Insulin
Nadav Kidron, CEO of Oramed Pharmaceuticals explains that 1 in 11 people suffer from Diabetes and this is predicted to get worse.
People with type 1 diabetes do not have any ability to produce insulin. This results in an accumulation of glucose in the blood stream causing many medical issues. The best treatment for excess glucose in the blood is the one that the body already uses - Insulin.
Find out how Oramed Pharmaceuticals is working on a way to deliver insulin orally.
Oramed's Oral Insulin
Diabetes affects over 500 million patients worldwide making it the most common disease known to man.
For decades people have unsuccesfully tried to deliver insulin orally.
Oramed's technology is now able to make this possible, making it safer than injections. This can better the lives of hundreds of millions of people around the world.
Oramed: A Game Changer For Diabetics
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies. Mr.
